1) Understand the potential of ctDNA assessment as a strong prognostic biomarker to inform recurrence in patients with peritoneal metastasis undergoing curative resection.
2) Understand the importance of ctDNA assessment as a stratification factor in designing clinical trials to inform further therapy.
3) Understand the potential role of NGS-based ctDNA assessment in discovering actionable targets for peritoneal disease.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation